Phase I study of 2′-3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine (Q28321882)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: November 1991)

Language	Label	Description	Also known as
English	Phase I study of 2′-3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine	scientific article (publication date: November 1991)

Statements

scholarly article

0 references

Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine (English)

0 references

Phase I study of 2′-3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine (English)

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

0 references

AIDS-related complex

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

K. J. Connolly

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1659189

23 October 2022

J. D. Allan

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1659189

23 October 2022

H. Fitch

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1659189

23 October 2022

L. Jackson-Pope

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1659189

23 October 2022

C. McLaren

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1659189

23 October 2022

R. Canetta

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1659189

23 October 2022

J. E. Groopman

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1659189

23 October 2022

language of work or name

0 references

publication date

November 1991

0 references

full work available at URL

https://api.elsevier.com/content/article/PII:000293439190182W?httpAccept=text/xml

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

https://api.elsevier.com/content/article/PII:000293439190182W?httpAccept=text/plain

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

American Journal of Medicine

0 references

91

0 references

5

0 references

471-8

0 references

Strategies for antiviral therapy in AIDS.

1

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides

2

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex

3

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

4

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

6

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

7

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

8

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group

10

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial

11

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives

12

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virus

14

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity

15

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity

16

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial

17

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

18

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial

19

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

Severe hypocalcaemia in AIDS patients treated with foscarnet and pentamidine

20

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex

21

1 reference

10.1016/0002-9343(91)90182-W

https://api.crossref.org/works/10.1016/0002-9343(91)90182-W

23 October 2022

Identifiers

10.1016/0002-9343(91)90182-W

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28321882&oldid=2133540546"